Literature DB >> 22571900

Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.

I Mederacke1, C Yurdaydin, A Großhennig, A Erhardt, Y Cakaloglu, K Yalcin, S Gurel, S Zeuzem, K Zachou, C Chatzikyrkou, H Bozkaya, G N Dalekos, M P Manns, H Wedemeyer.   

Abstract

Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNα-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNα-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by Cockcroft-Gault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNα-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR ≥ 20% was observed more often in patients during adefovir-containing treatment vs PegIFNα-2a alone (P < 0.05) which was confirmed by Kaplan-Meier analysis. Adefovir-containing but not PegIFNα-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNα-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22571900     DOI: 10.1111/j.1365-2893.2011.01560.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  3 in total

1.  Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.

Authors:  Ming-Tsung Lin; Yi-Hao Yen; Ming-Chao Tsai; Po-Lin Tseng; Kuo-Chin Chang; Cheng-Kun Wu; Tsung-Hui Hu
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

2.  Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B.

Authors:  Ye Zhang; Wei-Lu Zhang; Xiao-Wen Pang; Lin-Xu Wang; Xin Wei; Chang-Xing Huang; Xue-Fan Bai; Shuai Han; Lin-Na Liu; Jian-Qi Lian
Journal:  Virol J       Date:  2017-03-09       Impact factor: 4.099

3.  Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B.

Authors:  Qian Su; Yanyan Liu; Jiabin Li
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.